Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fosun’s Gland Acquisition Faces Indian Wall?

Executive Summary

Chinese group Fosun’s landmark buyout of Gland Pharma appears less likely to go through in India, at least for now, though some experts claim that the deal has always been a tricky one from the Indian standpoint. Indo-China border tensions are unlikely to make things any easier.

You may also be interested in...



Deal Watch: Takeda Continues Transaction Spree With Four More Deals

Takeda's recent deals include a license in Asian for Tesaro's PARP inhibitor Zejula. Meanwhile, Japanese rival Mitsubishi Tanabe is paying roughly $1bn to acquire Israel's NeuroDerm.

China Investment Roundup: Strategic Overseas Moves Target Product Acquisitions

R&D-based big pharma groups in China with sufficient cash flow are increasing their strategic investments in overseas companies and products with an eye on entry to the global market, while start-ups continue to actively raise new funds from venture capitalists.

Fosun On Course To Full Indian Clearance For Gland Buyout

After several rounds of deferral, an Indian investment board has approved Fosun’s acquisition of Gland Pharma, clearing the way for the first Chinese mega acquisition in the Indian pharmaceutical space, although the deal is still expected to require the go ahead from a Cabinet committee on economic affairs.

Topics

Related Companies

UsernamePublicRestriction

Register

SC099242

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel